background
rtpcr
test
identif
viral
nucleic
acid
current
standard
diagnost
method
diagnosi
diseas
technic
reason
limit
util
assay
onlarg
scalescreen
method
verifi
consecut
seri
symptomat
patient
clinic
inform
new
rapid
serolog
colorimetr
test
qualit
analyz
igmigg
express
provid
respect
standard
assay
respect
clinic
outcom
patient
resultsrapid
serolog
test
show
sensit
specif
respect
standard
assay
interestingli
perform
improv
day
symptom
appear
day
symptom
predict
valu
rapid
serolog
test
higher
standardassay
behaviour
two
immunoglobulin
evalu
respect
time
length
symptom
appaer
signific
differ
immunoglobulin
behaviour
shown
conclus
rapid
serolog
test
analyz
present
studi
candid
provid
inform
immunoreact
subject
exposur
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
recent
novel
coronaviru
first
report
caus
lethal
pneumonia
human
interperson
transmiss
china
subsequ
molecular
studi
confirm
origin
transmiss
pneumonia
due
novel
coronaviru
name
caus
new
corona
viru
diseas
diseas
rapidli
spread
asian
european
countri
italian
governmenthad
take
drastic
measur
contain
outbreak
action
roll
outhav
includ
establish
strict
criteria
defin
patient
whomoropharing
swabsshould
collect
molecular
pcr
diagnosi
quarantin
individualswho
may
contact
infect
peopl
measur
activ
sinc
week
trend
new
infect
casesin
itali
still
increas
new
casesdaili
sever
attempt
made
interpret
epidemiolog
trend
itali
expert
pinpoint
import
limit
possibilityof
make
earli
diagnosi
infect
well
imposs
detect
asymptomat
subject
carri
viru
rtpcr
test
identificationof
viral
nucleic
acid
current
standard
diagnost
method
diagnosi
howev
assay
practic
limit
annoy
method
obtain
biolog
materi
nasopharynx
rel
long
time
gener
result
need
certifi
laboratori
specif
expertis
limit
make
rtpcr
unsuit
quick
simpl
patient
screen
therefor
search
precis
rapid
simpl
test
quickli
identifi
infect
patient
larg
scale
screen
becom
urgent
prevent
viru
transmiss
ensur
time
treatment
patient
saw
swee
hock
school
public
health
nation
univers
singapor
http
recent
review
diagnost
test
infect
current
undergo
clinic
valid
list
dozen
assay
base
rtpcr
realtimepcr
ng
microfluid
twelv
immunoassay
base
evid
relat
igg
andigmwer
also
list
latter
experiment
attempt
base
previou
experi
epidem
viral
sar
infect
argu
igm
specif
antibodi
could
detect
blood
day
iggsom
day
later
also
specul
sinc
sarsal
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
belong
larg
famili
virus
caus
mer
sar
epidem
antibodi
seroconvers
similar
previous
mention
report
singapor
nation
univers
immunoassay
describ
avail
inform
regard
sensit
specif
vivadiag
tm
kit
produc
jiangsu
medom
medic
technolog
kit
http
accord
preliminari
data
avail
may
potenti
candid
reliabl
rapid
minut
test
test
report
base
util
antihuman
igg
anti
igm
recombin
antigen
repres
receptorbind
domain
spike
protein
base
assumpt
design
studi
verifi
clinic
inform
serolog
vivadiag
tm
test
provid
compar
standard
rt
pcr
lab
test
andregard
clinic
outcom
patientsto
purpos
set
upa
prospect
monoinstitut
ad
hoc
blind
independ
studi
enrol
seri
patient
march
rd
march
th
consecut
cohort
patient
access
emerg
room
ospedal
policlinico
consorzial
bari
diseas
orientingsymptom
enrol
patient
receiv
oropharing
swap
standard
rtpcr
analysi
simultan
venou
blood
sampl
vivadiag
tm
test
perform
registri
main
clinic
inform
compris
time
appear
symptom
collect
toghet
inform
consent
oropharing
swap
sampl
suddenli
analyz
rtpcr
laboratori
molecular
epidemiolog
public
health
hygien
unit
policlinico
hospit
bari
itali
region
refer
laboratori
identif
venou
blood
sampl
analyz
clinic
patholog
laboratori
certifi
head
e
savino
institut
biobank
certifi
head
paradiso
istituto
tumori
g
paolo
ii
ircc
bari
studi
approv
ethic
committe
istitutotumori
g
paolo
ii
ircc
bari
protocol
number
ce
nasopharyngealoropharyng
swab
weresubject
nucleic
acid
extract
magna
pure
roch
diagnost
mannheim
germani
accord
manufactur
instruct
presenc
e
gene
rdrp
gene
n
gene
viru
identifi
commerci
realtim
pcr
assay
assay
seegen
seoul
republ
korea
sampl
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
consid
posit
molecular
screen
three
gene
detect
moreov
realtim
rrtpcr
protocol
use
confirm
presenc
http
wwwwhointdocsdefaultsourcecoronaviruseuscdcrtpcrp
n
e
l
f
r
e
e
c
n
n
r
u
c
n
p
f
f
v
r
n
rapid
iggigm
test
rapid
iggigm
vivadiag
tm
test
combin
antibodi
test
kit
design
manufactur
jiangsu
medom
medic
technologiesth
test
base
later
flow
qualit
immunoassay
rapid
determin
presenc
absenc
human
specimen
whole
blood
serum
plasma
surfac
antigen
specif
bind
antibodi
includ
igm
igg
conjug
colloid
gold
nanoparticl
spray
conjug
pad
rapid
iggigm
combin
antibodi
test
strip
two
mous
antihuman
monoclon
antibodi
antiigg
antiigm
strip
two
separ
test
line
test
specimen
ad
sampl
port
follow
addit
sampl
dilut
buffer
specimen
flow
devic
igg
igm
antibodi
present
specimen
bound
antigen
label
gold
colorimetr
reagent
fix
conjug
pad
conjug
sampl
continu
travel
strip
igm
antibodi
bound
igm
line
igg
antibodi
bound
g
igg
line
specimen
contain
antibodi
label
complex
bind
test
presenc
igg
igm
antibodi
indic
redpurpl
line
specif
region
indic
deviceeach
test
evalu
two
oper
pictur
taken
case
disagr
pictur
evalu
third
parti
perform
thevivadiag
tm
test
compar
rtpcr
test
via
caret
r
packag
comput
paramet
need
accuraci
precis
recal
kappa
univari
multivari
logist
regress
perform
age
dichotom
use
median
cutoff
day
onset
symptom
also
transform
categor
variabl
day
day
day
day
day
analys
carri
outin
r
result
consid
signific
pvalu
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
subject
enrol
studi
rtpcr
test
rapidiggigm
test
perform
cohort
median
age
year
male
present
emerg
room
differ
time
onset
symptom
descript
symptom
wasavail
patient
fourteen
subject
asymptomat
time
came
emerg
room
patient
posit
rtpcr
test
posit
serum
igmiggtest
compar
rtpcrtest
serolog
test
show
accuraci
ci
sensit
specif
cohen
kappa
valu
whose
strength
agreement
accord
altman
consid
fair
patient
positiveserolog
testsbut
neg
rtpcrresult
distribut
percentag
posit
result
detect
test
broken
day
symptom
onset
shown
figur
aclear
increas
inposit
serolog
test
observ
day
elaps
symptom
appear
reach
day
symptom
onset
convers
highest
likelihood
posit
rtpcr
test
resultwa
day
symptom
onset
decreas
point
time
amongstth
asymptomat
posit
rtpcr
test
result
serolog
test
one
analysi
regardingth
behavior
igm
iggaccord
time
symptom
onset
describ
figur
minim
differ
behavior
two
immunoglobulin
respect
toth
time
symptom
appear
becam
evid
howev
patient
withvivadiag
tm
posit
test
neg
rtpcr
result
posit
igm
subject
result
posit
igg
univari
multivari
logist
regress
performedto
look
independ
variabl
predict
posit
vivadiag
tm
rtpcr
test
result
tabl
univari
multivari
analysesshow
age
day
symptom
onset
significantli
associ
vivadiag
tm
posit
day
symptom
onset
relat
posit
rtpcr
test
result
clinic
relev
socal
rapid
serolog
test
still
open
issu
sinc
data
current
avail
still
scarc
reason
analyz
perform
compar
standard
rtpcr
test
respect
time
onset
relat
symptom
end
set
monoal
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
institut
consecut
cohort
patient
test
assay
singl
qualifi
laboratori
design
studi
allow
us
specif
analyz
two
aspect
open
issu
concord
rapid
serolog
test
standard
molecular
test
trend
immunoglobulinsiggigmexpress
respect
onset
clinic
symptom
regard
degre
concord
two
test
result
report
tabl
clearli
show
precis
rapidserolog
test
vivadiag
tm
unsatisfactori
notabl
patient
molecular
test
also
posit
serolog
test
figur
impress
similar
perform
report
serolog
test
spain
germani
howev
first
import
inform
studi
concern
case
test
neg
molecular
test
posit
serolog
result
two
test
produc
similar
result
would
obviou
assay
look
differ
aspect
fact
molecular
test
demonstr
presenc
viru
sampl
specif
anatom
part
respiratori
system
kinet
immunoglobulinsi
devot
describ
bodi
react
viral
infect
neg
serolog
test
result
patient
posit
molecular
test
could
mean
latter
infect
subject
yet
reach
stage
develop
immunoglobulin
reaction
convers
subject
whose
serolog
test
show
presenc
specif
igg
andor
igm
antibodi
neg
molecular
test
may
consid
recov
data
shown
figur
seem
confirm
assumpt
molecular
test
yield
posit
result
earli
symptomat
phase
diseas
serolog
test
perform
better
late
phase
diseas
ie
day
symptom
appear
second
aspect
abl
analyz
studi
regard
seroconvers
kinet
immunoglobulin
respect
onset
relat
symptom
figur
show
behavior
two
immunoglobulin
respect
symptom
appear
interestingli
igg
igm
seem
behav
differ
base
number
day
elaps
symptom
appear
display
clear
progress
increas
along
cours
diseas
unexpect
find
contrast
common
think
concern
kinet
two
immunoglobulin
support
result
report
zhang
lou
reportingthat
detect
serolog
marker
igg
igm
similar
seroconvers
patient
antibodi
level
increas
rapidli
start
day
post
exposur
trend
occur
concomit
declin
viral
load
behavior
day
time
window
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
symptom
appear
accompani
improv
serolog
test
sensit
compar
standard
molecular
test
studi
import
limit
firstli
vivadiag
tm
test
base
colorimetr
evalu
igg
igm
band
oper
thu
impli
limit
qualit
interintraoper
evalu
produc
term
variabl
studi
aspect
partial
solv
resort
doubl
oper
evalu
take
pictur
test
result
reanalyz
third
parti
case
first
level
evalu
disagr
howev
regard
next
step
research
overcom
issu
met
use
quantit
immunoenzymat
method
analyz
specif
immunoglobulin
limit
studi
regard
fact
neutral
antibodi
use
vivadiag
tm
test
might
crossreact
coronaviru
antigen
like
sarscov
recombin
antigen
util
vivadiagi
receptor
bind
domain
spike
protein
inform
possibl
crossreact
corona
flu
virus
yet
studi
studi
urgent
need
definit
clarifi
point
studi
analyz
theclin
perform
rapid
serolog
test
vivadiag
tm
confirmedth
test
limit
applic
diagnosi
infect
compar
standard
molecular
test
howev
rapid
serolog
test
seem
provid
import
inform
concern
immunoreact
individu
infect
importantli
may
detect
previou
exposur
viru
current
healthi
person
trial
recent
regist
clinicaltrialgov
specif
address
issu
plan
investig
monitoringof
seroconvers
iggigm
healthi
subject
may
develop
relat
symptom
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
